Sign inThe deal brings AbbVie the late-stage atopic dermatitis antibody zumilokibart and an asthma combination candidate, with dilution to earnings expected through 2027 before accretion begins in 2032.
SEC filing
The approval, Milestone's first outside the United States, triggers a $2.0 million milestone payment and hands commercialization in Greater China to Everest Medicines.
SEC filing
The MASH treatment trial finished its final 72-week patient visit, with topline results still expected in the fourth quarter of 2026.
SEC filing
Luis Jodar joins as CMO and David McAvoy as CLO as Vaxcyte says VAX-31 Phase 3 topline data will arrive by end of October 2026 instead of the fourth quarter.
SEC filing
The company said a single 320 mg dose drove near-complete APRIL suppression and 60-75% IgA and Gd-IgA1 reduction through 12 weeks, supporting a possible every-12-week dosing schedule.
SEC filing
Records show the approval letter and label were issued days after the FDA's September 3 clearance of Ionis Pharmaceuticals' zilganersen.
Drugs@FDA, FDA press release (2)
Medicus Pharma Inc. licensed rights to Pfizer's early clinical-stage asset CD228V, agreeing to pay up to $27 million in near-term fees plus potential milestones exceeding $1 billion.
SEC filing
Liquidia plans to start the Phase 2a RE-WARM study in October 2026, within the fourth quarter timeframe cited in its announcement.
SEC filing
The September 2, 2026 amendment restructures the Remix merger into two sequential mergers and revises how the concurrent private placement can be funded.
SEC filing
Can-Fite BioPharma said patients across both arms of its Namodenoson HCC trial are surviving longer than the study's design assumptions predicted, prompting consideration of an earlier interim analysis.
SEC filing
The "Aspire" study failed to show a benefit on cognitive scoring or a composite responder measure, prompting a review of the drug program and cost cuts.
SEC filing
The company also disclosed a Nasdaq bid-price deficiency notice and reported that all 13 tracked patients in ALLOHA Cohort C show complete donor chimerism.
SEC filing
Cardiovascular gene-editing company reports first clinical data expected in H1 2027 and cash runway into H1 2029 after $155.5 million IPO and Sanofi private placement.
SEC filing
The Morrisville, North Carolina biotech reported the offering fully sold to eight investors, in a notice signed September 2, 2026.
SEC filing
The company notified Yorkville on August 31, 2026 that it was ending the equity line agreement, effective September 8, 2026.
SEC filing
Attovia said its Phase 1b trial produced early clinical proof of concept for ATTO-1310 in itch conditions, with full data due in the fourth quarter and two Phase 2 studies planned for the first half of 2027.
SEC filing
The agreement, dated September 1, 2026, covers manufacturing of bezuclastinib's spray-dried dispersion and tablet forms.
SEC filing
The September 2, 2026 filings seek accelerated U.S. approval and U.K. authorization for ifezuntirgene inilparvovec, backed by three-year Phase I/II data.
SEC filing
Fawzi Benzaghou, M.D., will leave the company on September 30, 2026, under a mutual agreement disclosed in an 8-K filing.
SEC filing
The companies amended their license agreement to launch a three-phase Expansion Program advancing four AI-discovered compounds toward lead nomination in cardiac disease and obesity.
SEC filing (2)
The company disclosed in an SEC filing that its finance chief will step down effective November 6, 2026.
SEC filing
Lind Global Asset Management consented to VolitionRx's above-cap ATM sales and waived related default remedies under existing notes and warrants.
SEC filing
Clearmind Medicine said Part C of its CMND-100 study is one-third enrolled, with three patients dosed at each of two Israeli medical centers.
SEC filing
The merger closed September 1, 2026, converting Crinetics shares into $85.00 per share in cash and installing new leadership at the surviving subsidiary.
SEC filing
The company lowered the mining rig threshold in its merger agreement from 2,000 to 500 and is pursuing matching changes to related financing and asset agreements.
SEC filing
The company said 7-day rat and dog studies inform dosing for the next stage of IND-enabling work as it targets a Q1 2027 IND submission.
SEC filing
The private placement closed September 1, 2026, after initial purchasers fully exercised their option for additional notes, with proceeds earmarked partly for oncology and debt repayment.
SEC filing
The Nasdaq-listed biotech also disclosed a $7.74 million financing with 3i, LP tied to overdue payments under its Series C preferred stock terms.
SEC filing (2)
The Naples, Florida company disclosed the leadership change alongside annual meeting results including approval of reverse stock splits and share issuances tied to a J.J. Astor & Co. note.
SEC filing
Charles Wagner will hand off the CFO role but stay on as chief operating officer, per an 8-K filed with the SEC.
SEC filing
The company also elevated Ajay Royan to lead independent director and appointed Ian Sheffield to the board as VYD2311 trial results near completion.
SEC filing
The company signed its underwriting agreement and set final terms for the stock and warrant offering that priced August 31, 2026, closing September 2.
SEC filing (3)
Charlton, a pediatric endocrinologist with rare disease drug development experience, joined effective September 1, 2026 as Polaryx prepares to start its SOTERIA trial in the fourth quarter.
SEC filing
The California biotechnology company reported $25,000 sold toward the offering as of September 1, 2026, while its filing lists zero investors as having invested.
SEC filing
The filing covers options set to vest over eight quarterly installments starting August 19, 2026, with a total potential offering value of $261,987.
SEC filing
VolitionRx converted portions of its senior secured convertible notes into common stock across seven transactions dated August 27 and August 31, 2026.
SEC filing